Loading clinical trials...
Loading clinical trials...
A Phase I Randomized, Observer-blind, Placebo-controlled Trial of a Haemophilus Influenzae Serotype A (Hia) Glycoconjugate Vaccine With Alum Adjuvant in Young Adults 18 to 40 Years of Age
Conditions
Interventions
Haemophilus influenzae type a (Hia) glycoconjugate vaccine
Locations
2
Canada
Canadian Center for Vaccinology (CCfV)
Halifax, Nova Scotia, Canada
McGill University Health Centre (MUHC) Vaccine Study Centre
Montreal, Quebec, Canada
Start Date
May 29, 2024
Primary Completion Date
October 15, 2024
Completion Date
September 15, 2025
Last Updated
April 30, 2025
Lead Sponsor
InventVacc Biologicals Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions